UK’s life sciences sector continues to attract talent despite Brexit fear

26 Nov 2019

The largest area of growth has been within biotechnology companies, where job openings increased by 35%.

Despite the on-going political and economic turmoil, demand for professionals to work within the UK’s life sciences sector increased by 25% in 2019, according to data from the Association of Professional Staffing Companies (APSCo) and business intelligence specialist, Vacancysoft.

UK’s life sciences sector continues to attract talent despite Brexit fear

The research also revealed that, while pharmaceutical firms continue to provide the lion’s share of professional opportunities, the largest area of growth has been within biotechnology companies, where job openings increased by 35%. Demand for professionals in clinical research organisations was also high, rising by 25% year-on-year.

In terms of function, R&D remains the strongest area for hiring, with vacancies up by 31% since 2018. Demand for quality assurance specialists was also notable, rising by 28%. By specialist role, clinical researchers were noted as a fast growth profession, increasing by 25% within clinical research organisations and 10% across Big Pharma.

South East England is the most dominant region for hiring life sciences professionals, accounting for 37% of all vacancies in the UK in 2019. Since 2018, job openings in the region have increased by 22%. In London, vacancies rose by 30% over the same period and now account for 18% of total roles. While accounting for a smaller proportion of overall vacancies, the East Midlands, Yorkshire & the Humber, South West England and North East England all noted 50%+ year-on-year growth in demand for professionals to work in the sector.

Research organisation, Covance, is now the largest single hirer of life sciences professionals in the UK, with vacancies up by 111% year-on-year in 2019. PRA Health Sciences, Envigo and AstraZeneca are also major players, with vacancies at these firm increasing by 210%, 71% and 21%, respectively.

Ann Swain, Chief Executive of APSCo, commented: “The UK life sciences sector is the most productive in the G7, and it’s encouraging to see that the government is fully committed to supporting its growth and by default, jobs in the sector. There are ambitious plans in the pipeline - as outlined in Sir John Bell’s Life Sciences Industrial Strategy - which focus on developing cutting-edge technology and new innovations along with £1.2 billion of new investment that will further strengthen the UK as a world-leading science base.”

James Chaplin, CEO of Vacancysoft, added: “The life sciences sector in the UK continues to go from strength to strength, and is undoubtedly a critical part of the nation’s economic strength. It contributes over £70 billion a year to the economy and supports 240,000 jobs - with no signs of slowing down. It is also unsurprising to see that R&D continues to be one of the strongest areas for hiring, as the government has recently announced that it is committed to raising the intensity of R&D spend to reach 2.4% of GDP in the UK by 2027.”

Read More

Related news

UK experiences a 'baby boom' of new life sciences ventures

UK experiences a 'baby boom' of new life sciences ventures

2 Dec 2019

Unprecedented levels of investment cited as a major force driving the expansion.

Read more 
Winners of the 16th Pharma Awards

Winners of the 16th Pharma Awards

11 Nov 2019

Companies and individuals from across the whole pharma supply chain recognised for their excellence and commitment.

Read more 
‘FDA should withdraw ANDAs’ says expert

‘FDA should withdraw ANDAs’ says expert

21 Oct 2019

CPhI Worldwide's Annual Report suggests repeat offenders of regulatory infringements should be barred from importing into the US.

Read more 
Sanofi opens its first digitally-enabled, continuous manufacturing facility

Sanofi opens its first digitally-enabled, continuous manufacturing facility

15 Oct 2019

One of the first digital manufacturing facilities in the world to use continuous, intensified biologics production technology.

Read more 
EC approves its first plant-derived cannabis-based medicine

EC approves its first plant-derived cannabis-based medicine

24 Sep 2019

Epidyolex (cannabidiol) approved for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

Read more 
Integrating glucose sensing and insulin delivery technologies

Integrating glucose sensing and insulin delivery technologies

18 Sep 2019

Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin.

Read more 
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

9 Sep 2019

Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.

Read more 
China relaxes import regulations to improve access and availability of affordable medicines

China relaxes import regulations to improve access and availability of affordable medicines

3 Sep 2019

The potential for generics to support the healthcare needs of China is significant.

Read more 
Exciting new vaccine targets killer disease TB

Exciting new vaccine targets killer disease TB

28 Aug 2019

Australian researchers produce early-stage vaccine which is inhaled into the lungs.

Read more 
Switzerland overtakes Germany as Europe’s biggest drug delivery innovator

Switzerland overtakes Germany as Europe’s biggest drug delivery innovator

16 Aug 2019

Pipeline of new drugs has helped drive increased innovation in packaging and drug delivery devices.

Read more